APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$41.02
+0.00% today
Updated 2026-05-14
Market cap
$5.25B
P/E ratio
38.34
P/S ratio
4.75x
EPS (TTM)
$1.07
Dividend yield
—
52W range
$16 – $41
Volume
7.4M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
8.0
Growth
A5.5
Quality
C+7.5
Profitability
B+6.3
Valuation
B5/9
Piotroski F-Score
Moderate
-2.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$40.93
-0.22%
12-Month target
$1.22
-97.03%
Intrinsic (DCF)
$194.37
Margin of safety
+88.52%
0 Strong Buy1 Buy19 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 33.22% — strong efficiency
+ Revenue growth 60.90% QoQ
+ 88.52% below intrinsic value
Risks
- Altman Z -2.39 — distress zone
- Negative free cash flow $-60.97M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $75.42M | $396.59M | $781.37M | $1.00B | $1.11B |
| Net income | $-652.17M | $-528.63M | $-197.88M | $22.39M | $18.66M |
| EPS | — | — | — | — | $1.07 |
| Free cash flow | $-515.27M | $-595.51M | $-88.27M | $45.01M | $-60.97M |
| Profit margin | -864.70% | -133.29% | -25.32% | 2.23% | 12.10% |
Peer comparison
Smart narrative
Apellis Pharmaceuticals Inc trades at $41.02. representing a P/E of 38.34x trailing earnings. Our Smart Value Score of 50/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -2.39, it sits in the distress. TTM revenue stands at $1.11B. with profit margins at 12.10%. Our DCF model estimates intrinsic value at $194.37.
Frequently asked questions
What is Apellis Pharmaceuticals Inc's stock price?
Apellis Pharmaceuticals Inc (APLS) trades at $41.02, on a P/E of 38.3x and a P/S of 4.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Apellis Pharmaceuticals Inc overvalued?
Apellis Pharmaceuticals Inc carries a Smart Value Score of 50/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $194.37 versus the $41.02 price, a 88.5% margin of safety on a cash flow basis.
What is the price target of Apellis Pharmaceuticals Inc (APLS)?
The 12-month analyst consensus target is $40.93, about 0.2% below the current $41.02. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Apellis Pharmaceuticals Inc (APLS)?
Our DCF model estimates intrinsic value at $194.37, a +88.5% margin of safety versus today's $41.02. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Apellis Pharmaceuticals Inc's revenue?
Apellis Pharmaceuticals Inc's trailing twelve-month revenue is $1.11B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Apellis Pharmaceuticals Inc's Altman Z-Score is -2.39, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.75x
ROE33.22%
Beta-0.25
50D MA$31.53
200D MA$25.64
Shares out0.13B
Float0.08B
Short ratio—
Avg volume7.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—